General Notices

• NCCIH Announces Availability of Frequently Asked Questions (FAQs) for HEAL Sickle Cell Disease Pain Management Funding Opportunities RFA-AT-22-004 and RFA-AT-22-005
  (NOT-AT-22-006)
  National Center for Complementary and Integrative Health
  

• Pre-Application Webinar for RFA-CA-21-060, RFA-CA-21-061, and RFA-CA-21-062: "The NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers"
  (NOT-CA-22-019)
  National Cancer Institute
  

• Request for Information on Proposed Updates and Long-Term Considerations for the NIH Genomic Data Sharing Policy
  (NOT-OD-22-029)
  Office of the Director, NIH
  

Notice of Changes to Funding Opportunities

• Notice of Change to Eligibility Information in PAR-21-351 "NIA Career Transition Award (K22 Independent Clinical Trial Not Allowed)"
  (NOT-AG-22-002)
  National Institute on Aging
  

• Notice of Early Expiration of PAR-19-078, Molecular and Genetic Characterization of Inborn Errors of Immunity (R01 Clinical Trial Not Allowed)"
  (NOT-AI-22-005)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Early Expiration of PAR-19-079, Molecular and Genetic Characterization of Inborn Errors of Immunity (R21 Clinical Trial Not Allowed)"
  (NOT-AI-22-006)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Early Expiration of PA-19-077, Accelerating Malaria Vaccine Discovery (R01 Clinical Trial Not Allowed)"
  (NOT-AI-22-009)
  National Institute of Allergy and Infectious Diseases
  

• Notice of NIAMS' Participation in PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)"
  (NOT-AR-21-028)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  

• Notice of Clarification of Award Budget Instructions for Specific Aims in RFA-ES-21-007, Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)
  (NOT-ES-22-004)
  National Institute of Environmental Health Sciences
  

• Notice of Change to Key Dates for PAR-19-261, "Chemical Screening and Optimization Facility (X01 Clinical Trial Not Allowed)"
  (NOT-HD-21-054)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Change in Eligible Organizations for PAR-21-312, "Genomic Curriculum Development for Medical Students (R25 Clinical Trial Not Allowed)"
  (NOT-HG-22-005)
  National Human Genome Research Institute
  

• Notice of Change of the Locus of Review and Application Types Allowed for PAR-22-035, "Mood and Psychosis Symptoms during the Menopause Transition (R01 Clinical Trial Optional)"
  (NOT-MH-22-075)
  National Institute of Mental Health
  

• Notice of Change of the Locus of Review and Application Types Allowed for PAR-22-036, "Mood and Psychosis Symptoms during the Menopause Transition (R21 Clinical Trial Optional)"
  (NOT-MH-22-076)
  National Institute of Mental Health
  

• Notice of Participation of the National Institute of Nursing Research (NINR) in PAR-21-287, Effectiveness of School-Based Health Centers to Advance Health Equity (R01 Clinical Trial Optional)
  (NOT-NR-22-007)
  National Institute of Nursing Research
  

• Notice of Correction to Award Information for RFA-RM-22-006, " Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed)"
  (NOT-RM-22-005)
  Office of Strategic Coordination (Common Fund)
  

• Notice of Change to Participant Eligibility, Participant Costs and Other Attachments to Funding Opportunity Announcement PAR-21-339, Limited Competition: NCATS Clinical and Translational Science Award (CTSA) Program Research Education Grants Program (R25)
  (NOT-TR-22-010)
  National Center for Advancing Translational Sciences
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
  (NOT-DA-21-084)
  National Institute on Drug Abuse
  

• Notice of Intent to Publish a Funding Opportunity Announcement for NIDCD National Human Ear Resource Network (U24)
  (NOT-DC-22-006)
  National Institute on Deafness and Other Communication Disorders
  

• Notice of Intent to Publish a Funding Opportunity Announcement for NIH Neuroscience Doctoral Readiness Program (DR. Program) (R25 Clinical Trial Not Allowed)
  (NOT-NS-22-039)
  National Institute of Neurological Disorders and Stroke
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Research on Community Level Interventions to Prevent Firearm and Related Violence, Injury and Mortality
  (NOT-OD-22-028)
  Office of Behavioral and Social Sciences Research
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Molecular and Genetic Characterization of Inborn Errors of Immunity
  (NOT-AI-21-082)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Special Interest (NOSI): Accelerating Malaria Vaccine Discovery
  (NOT-AI-22-014)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Special Interest (NOSI): RNA Modifications in Cancer Biology
  (NOT-CA-22-003)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Research in the Chemistry and Pharmacology of Addictive Drugs
  (NOT-DA-23-002)
  National Institute on Drug Abuse
  

Funding Opportunities

• Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
  (PAR-22-031)
  National Institute of Mental Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
  (PAR-22-032)
  National Institute of Mental Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  Application Receipt Date(s): January 07, 2025
  
  

• NIGMS National and Regional Resources (R24 - Clinical Trial Not Allowed)
  (PAR-22-065)
  National Institute of General Medical Sciences
  Application Receipt Date(s): June 14, 2024
  
  

• High Impact, Interdisciplinary Science in NIDDK Research Areas (RC2 Clinical Trial Optional)
  (PAR-22-069)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): October 30, 2024
  
  

• Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed)
  (RFA-AG-22-030)
  National Institute on Aging
  Application Receipt Date(s): January 10, 2022
  
  

• National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U2C - Clinical Trial Not Allowed)
  (RFA-DK-21-027)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 08, 2022
  
  

• Fostering Research With Additional Resources and Development (FORWARD) Urology Centers (P20 Clinical Trial Not Allowed)
  (RFA-DK-21-032)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 24, 2022
  
  

• Coordinating Unit for the National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U24 - Clinical Trial Not Allowed)
  (RFA-DK-21-035)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 08, 2022
  
  

• Conformance with the Egg Regulatory Program Standards (U2F) [Clinical Trial Not Allowed]
  (RFA-FD-22-006)
  Food and Drug Administration
  Application Receipt Date(s): January 31, 2022 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Child Health Research Career Development Award (CHRCDA) Program (K12 Clinical Trial Not Allowed)
  (RFA-HD-23-010)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): March 30, 2022